Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

53 results about "Blood-forming stem cell" patented technology

Embryonic stem cells can develop into every type of cell in the body.) Hematopoietic stem cells divide to form more blood-forming stem cells, or they mature into one of three types of blood cells: white blood cells, which fight infection; red blood cells, which carry oxygen; and platelets, which help the blood to clot.

Pharmaceutical composition for promoting hematopoiesis and preparation method thereof

The invention relates to a pharmaceutical composition for promoting hematopoiesis, which comprises hemopoietic stem cells and melanterite, wherein the preferred hemopoietic stem cells are cells which are imported with an expression vector with cell factor genes. The invention also relates to a method for preparing the pharmaceutical composition and application of the pharmaceutical composition in preparing a medicament for treating the damage state of hematopoietic function, wherein the hemopoietic stem cells and the melanterite have the function of synergistically promoting the hematopoiesis.
Owner:SOUTHWEST HOSPITAL OF CHONGQING

Hematopoietic stem cell storing and pairing device

The invention provides a hematopoietic stem cell storing and pairing device, and belongs to the technical field of medical equipment. The hematopoietic stem cell storing and pairing device comprises astorage box, a take-placing opening is formed in the upper wall of the storage box, and a test tube mounting assembly and a test tube take-placing assembly are arranged in the storage box. The test tube mounting assembly comprises a storage rack and a second motor which is arranged at the bottom of the storage rack and is connected with the storage rack through a rotary shaft. The hematopoietic stem cell storing and pairing device has the advantages that taking and placing are convenient, and the storage effect is good; when a test tube needs to be taken out, the second motor drives the storage rack to rotate, the test tube needing to be taken out is moved to be below clamping plates, a driving rod drives a driving plate to move downwards, and the clamping plates are utilized for clampingthe test tube. Then the driving rod drives the driving plate and the clamping plates clamping the test tube to move upwards to the take-placing opening, the test tube can be taken out, and precise selection of the test tube is achieved; and meanwhile all test tube samples are prevented from be exposed to the external environment, and hematopoietic stem cells are prevented from being contaminatedby the external environment.
Owner:李容尔

Method for separating and purifying hemopoietic stem cells derived from umbilical cord blood and placentas

The invention provides a method for separating and purifying hemopoietic stem cells derived from umbilical cord blood and placentas and relates to a method for separating and purifying stem cells, aiming at solving the problems that a conventional hemopoietic stem cell separation and purification method only pays attention to the added amount of HES (Hydroxyethyl Starch) according to the volume ofa blood sample, and does not consider the ratio change of red blood cells in different blood samples. According to the method provided by the invention, the quantity of the red blood cells in umbilical cord blood and placenta cell suspended liquid is detected through a blood analyzer, and the HES is added according to an accurate ratio; then an accurate emission amount of the red blood cells andblood plasma, and the weight of the purified hemopoietic stem cells are realized through formula calculation and a blood flow speed controller, so that accurate adding of cryopreservation liquid is realized and the yield of the hemopoietic stem cells is maximized; separation and purification operation has rules to follow so that a condition that the adding of the HES and the cryopreservation liquid and the emission of the red blood cell plasma are carried out according to experience of people is avoided, the recycling of the hemopoietic stem cells in the samples and quality safety of the hemopoietic stem cells after being cryopreserved are ensured, and quality deviation caused by the operation of people is avoided.
Owner:天晴干细胞股份有限公司

Application of adult stem cells in treating malignant solid tumors

The invention relates to application of adult stem cells in treating malignant solid tumors, in particular to application of adult stem cells in preparing a cell preparation for treating malignant solid tumors. The inventor fuses human mesenchymal stem cells and human hemopoietic stem cells respectively with human esophageal carcinoma cells, and injects the fusion cells into SCID (severe combined immune deficiency) / mice and nude mice, and as a result, the emerging rate of tumors of the fusion cells is obviously reduced and the volume thereof is also reduced. The stem cell preparation provided by the invention can obviously inhibit the growth of malignant solid tumors.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Lentiviral vector with efficient infectivity and multiplication capacity promoting effect for T cells and hematopoietic stem cells

The invention provides a method for constructing a lentiviral vector with efficient transfection capacity and efficient bioactivity expression capacity. Experimental results show that the viral infection efficiency can be increased by 30-70% by using the method; in addition, the inventor unexpectedly finds that the proliferation of the T cells can also be effectively stimulated by using the technical scheme, and furthermore the treatment process of CAR-T cells is simplified, and the cost is reduced.
Owner:SHANGHAI JI KAI GENE TECH CO LTD

SG fusion protein

The invention relates the technical field of medical biology; currently, the medicines which is often used for hematopoiesis and restoring injured tissues clinically are GM-CSF, G-CSF and GM-CSF that mainly take effect on colony forming unit-granulocyte-monocyte to promote proliferation and differentiation, so as to have action on hemopoietic stem cell, medullary system multipotent progenitor cell as well as erythroid and macronucleus system hematopoiesis. But the effect of promoting hematopoiesis and proliferation of the medicines is provisional, the maintaining time is short, and the effects disappear when the medicines are stopped being taken. The invention provides a fusion protein which is used for preventing and treating hematopoiesis damage caused by radiation treatment and chemo-treatment and has the function of enhancing immunity. The gene of the SG fusion protein of the invention has the nucleotide sequence which is shown as SEQ ID NO: 4 and has the whole length of 850bp. The experiments of biology in vitro shows that the SG fusion protein of the invention can promote bone marrow colony cells to form, can effectively lead immature dendritic cells to be chemotactic, and has stronger function compared with GM-CSF.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Composition Containing Osteopontin for Differentiating Natural Killer Cell as an Active Ingredient and a Method of Differentiation Using Thereof

The present invention relates to a composition for differentiating natural killer cells comprising osteopontin (OPN) as an active ingredient and a method for differentiation using the same. More precisely, osteopontin of the present invention accelerates differentiation of natural killer cells from hematopoietic stem cells and increases cytotoxic activity of natural killer cells, so that it can be effectively used as a composition for differentiating natural killer cells. OPN of the present invention regulates differentiation of natural killer cells capable of killing cancer cells, so that it can be effectively used for the treatment of cancer.
Owner:KOREA RES INST OF BIOSCI & BIOTECH

Methods of stem cell manipulation for immunotherapy

Methods for the expansion of blood stem cells and their activation as dendritic cells in a scheme for adjuvant immune therapy of patients with cancer or other diseases. The utility of combining a trade secret formulation of INCELL's M3(TM) medium in the expansion and activation of immune system stem cells and differentiated cells, including dendritic cells, with subsequent immunoreactivity against tumor cell antigens is demonstrated. The patent also describes long-term culture and cryopreservation of cells that maintain their reactivity and functionality, suggesting their potential use as universal donor cells. Furthermore, it describes how a dendritic cell activation kit can be developed using the approaches and the cell and media tools described.
Owner:MOYER MARY PAT +3
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products